Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 5/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17199240 | 1.00 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL12508446 | 0.83 | PDPK1 (0.50) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL22073767 | 0.83 | PDPK1 (0.50) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL17914139 | 0.83 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL25843271 | 0.83 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL12509155 | 0.83 | PDPK1 (0.50) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL17914140 | 0.83 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL22814083 | 0.83 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL25843217 | 0.83 | DRD2 (0.42) | DRD2S1PR1DRD1DRD4DRD5 | |
| SCHEMBL10210350 | 0.81 | OPRL1 (0.35) | S1PR1MAOBMAOAOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165236-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS LLC | 2017-06-15 | — | — | US | disclosed |
| US-9394264-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299149-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2015066515-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | DRD2 2627/4885S1PR1 1/4885DRD1 3148/4885 |
| US-20150299149-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | DRD2 2353/4885S1PR1 1/4885DRD1 2851/4885 |
| US-20170165236-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | S1PR1, S1PR2, S1PR4 | DRD2 2008/4885S1PR1 1/4885DRD1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.